Exemplar Genetics in partnership with Mayo Clinic launched a new company, Cytotheryx, focused on the development of a high-quality source of human liver cells or hepatocytes for clinical research, according to a press release.
“This collaboration combines our focus on unmet needs of patients with an innovative way to drive development of new therapies,” Andrew Danielsen, vice-chair of the department of business development at Mayo Clinic, said in the release.
Exemplar Genetics will provide business and technical resources for the company, while Mayo Clinic will use any revenue it receives to support nonprofit missions in patient care, education and research.
“Throughout the United States and the world there is a desperate need for a high-quality source of [hepatocytes] for medical research and regenerative medicine applications,” John R. Swart, president of Exemplar Genetics, said in the release. “Cytotheryx has brought together the team and technology to deliver on that need.”
Cytotheryx is headquartered in Rochester, Minnesota.